November 2023

Actimab-A can target CD33 positive immune suppressing myeloid derived suppressor cells and restore T cell proliferation and effector responseSolid tumor MDSC infiltration and uptake of Actimab-A confirmed by SPECT/CT imaging in a humanized non-small cell lung cancer model NEW YORK, Nov. 6, 2023 /PRN

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: